Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
Quick Facts
What This Study Found
At 24 weeks, semaglutide reduced the hepatic steatosis index (HSI) by 2.36 and the fibrosis-4 index (FIB-4) by 0.075.
Key Numbers
How They Did This
The study was a multicenter, prospective, pre-post, uncontrolled cohort analysis involving patients with type 2 diabetes treated with semaglutide.
Why This Research Matters
Improving liver health in diabetic patients can reduce the risk of severe liver disease. This study highlights semaglutide's potential benefits beyond blood sugar control.
What This Study Doesn't Tell Us
The study was uncontrolled and lacked a comparison group, which may affect the reliability of the findings.
Trust & Context
- Original Title:
- Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
- Published In:
- Revista clinica espanola, 223(3), 134-143 (2023)
- Authors:
- Carretero-Gómez, Juana, Carrasco-Sánchez, Francisco Javier, Fernández-Rodríguez, José María, Casado-Escribano, Pedro, Miramontes-González, José Pablo, Seguí-Ripoll, José Miguel, Ena, Javier, Arévalo-Lorido, José Carlos
- Database ID:
- RPEP-06775
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06775APA
Carretero-Gómez, Juana; Carrasco-Sánchez, Francisco Javier; Fernández-Rodríguez, José María; Casado-Escribano, Pedro; Miramontes-González, José Pablo; Seguí-Ripoll, José Miguel; Ena, Javier; Arévalo-Lorido, José Carlos. (2023). Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.. Revista clinica espanola, 223(3), 134-143. https://doi.org/10.1016/j.rceng.2022.12.001
MLA
Carretero-Gómez, Juana, et al. "Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.." Revista clinica espanola, 2023. https://doi.org/10.1016/j.rceng.2022.12.001
RethinkPeptides
RethinkPeptides Research Database. "Effect of semaglutide on fatty liver disease biomarkers in p..." RPEP-06775. Retrieved from https://rethinkpeptides.com/research/carretero-gomez-2023-effect-of-semaglutide-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.